John Overdeck’s Citius Pharmaceuticals CTXR Stock Holding History

John Overdeck’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6K	Buy	17,494 +4,356	+33%	+$2.95K	﹤0.01%	5003
2026 Q1	$11.8K	Sell	13,138 -47,700	-78%	-$38.5K	﹤0.01%	4524
2025 Q4	$47.3K	Buy	60,838 +39,035	+179%	+$48.8K	﹤0.01%	3942
2025 Q3	$27K	Buy	21,803 +8,929	+69%	+$12.4K	﹤0.01%	3579
2025 Q2	$20.5K	Buy	+12,874	New	+$11.8K	﹤0.01%	3118
2023 Q3	–	Sell	-1,561	Closed	-$46.8K	–	2991
2023 Q2	$46.8K	Buy	+1,561	New	+$51.4K	﹤0.01%	2837
2022 Q3	–	Sell	-2,226	Closed	-$51K	–	2527
2022 Q2	$51K	Buy	+2,226	New	+$61K	﹤0.01%	2343
2022 Q1	–	Sell	-6,478	Closed	-$249K	–	3016
2021 Q4	$249K	Buy	6,478 +713	+12%	+$32.3K	﹤0.01%	3775
2021 Q3	$293K	Buy	+5,765	New	+$289K	﹤0.01%	3687

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

John Overdeck's CTXR Position: Q2 2026 in Review

John Overdeck increased its Citius Pharmaceuticals (CTXR) stake by 33% in Q2 2026, buying an estimated $2.95K and bringing the position to 17,494 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5003.

John Overdeck first reported a position in CTXR in Q3 2021 and has held it in 9 quarters since. The position peaked at $293K in Q3 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

John Overdeck held 17,494 shares of Citius Pharmaceuticals worth $10.6K as of Q2 2026.
John Overdeck bought 4,356 Citius Pharmaceuticals shares in Q2 2026, an estimated $2.95K.
Citius Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #5003 holding.
John Overdeck first reported a position in Citius Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
John Overdeck's Citius Pharmaceuticals position peaked at $293K in Q3 2021.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.